State Street Corp Raises Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM)

State Street Corp grew its holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 23.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,566 shares of the company’s stock after buying an additional 21,760 shares during the quarter. State Street Corp owned 0.44% of Contineum Therapeutics worth $2,174,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Johnson & Johnson purchased a new stake in Contineum Therapeutics during the 2nd quarter worth approximately $34,853,000. Perceptive Advisors LLC purchased a new position in Contineum Therapeutics in the 2nd quarter valued at $27,589,000. Versant Venture Management LLC acquired a new stake in Contineum Therapeutics during the 2nd quarter worth $16,169,000. FMR LLC boosted its stake in Contineum Therapeutics by 115.4% during the 3rd quarter. FMR LLC now owns 696,927 shares of the company’s stock worth $13,339,000 after purchasing an additional 373,327 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Contineum Therapeutics in the second quarter valued at about $2,642,000.

Contineum Therapeutics Trading Up 1.2 %

Contineum Therapeutics stock opened at $14.65 on Thursday. Contineum Therapeutics, Inc. has a fifty-two week low of $12.33 and a fifty-two week high of $22.00. The firm has a 50 day moving average price of $15.42 and a 200 day moving average price of $17.57.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01. As a group, equities research analysts anticipate that Contineum Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CTNM has been the subject of several research reports. Royal Bank of Canada dropped their price objective on shares of Contineum Therapeutics from $32.00 to $31.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Robert W. Baird assumed coverage on Contineum Therapeutics in a research report on Tuesday, October 22nd. They set an “outperform” rating and a $32.00 price objective on the stock. Finally, Baird R W raised shares of Contineum Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $29.25.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).